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Summary:  Whilst the incidence of invasive pneumococcal disease (IPD) in infants in England 
remains low, the risk of IPD is significantly higher in premature infants compared to term infants.  
Changes to the infant pneumococcal immunisation schedule may disproportionally affect premature 
infants. 
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Abstract 
Background:  Invasive pneumococcal disease (IPD) has declined significantly since the introduction 
of pneumococcal conjugate vaccines (PCV).  It is not known whether certain infant populations 
remain at higher risk of IPD in countries with established PCV13 programmes.  We aimed to describe 
the epidemiology, clinical characteristics, serotype distribution and outcomes of IPD in infants, and 
to estimate the relative risk of PCV13-type, non-PCV13 type and overall IPD in premature infants 
compared to term infants during a four-year period after the PCV13 programme was established.  
Methods: 
Prospective, enhanced national surveillance of laboratory-confirmed IPD in England in infants aged 
<1 year diagnosed during 2013-16 
Results 
There were 517 cases of IPD (incidence: 19/100,000 infants).  Incidence was significantly higher in 
premature infants compared with those born at term (49/100,000 vs 17/100,000; incidence rate 
ratio (IRR) 2.87; p<0.001) with infants born below 28 weeks gestation having the highest incidence 
(150/100,000; IRR 8.8; p<0.001).  Of the 454 IPD cases with serotyped isolates, most were caused by 
non-PCV13 serotypes (369 cases, 71.4%), with 85 cases (16.4%) due to PCV13 serotypes.  There were 
31 deaths (case fatality rate 6.2%; 95% CI, 4.3-8.6%).  Premature infants did not have a higher CFR 
than term infants (p=0.62). 
Conclusion & relevance 
IPD incidence in infants remains lower than rates reported prior to PCV7 introduction in England. 
The risk of IPD remains significantly higher in premature infants compared to infants born at term, 
for both PCV13 and non-PCV13 serotypes.  Any changes to the infant PCV13 immunisation schedule 
may disproportionally affect premature infants. 
Keywords: Invasive pneumococcal disease; Infant; Pneumococcal conjugate vaccines; 
Infant, premature 
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Background 
Streptococcus pneumoniae is a major cause of meningitis, septicaemia and pneumonia worldwide 
and is associated with significant morbidity and mortality, especially in young children, the elderly 
and those with underlying health conditions [1–3].  There are currently 92 distinct pneumococcal 
serotypes based on polysaccharide capsular differences [4–6]. Pneumococcal conjugate vaccines 
(PCVs) have been part of the UK infant immunisation programme since 2006, initially using a vaccine 
covering the 7 most prevalent pneumococcal serotypes causing invasive pneumococcal disease (IPD) 
in children (PCV7, Prevenar®, Pfizer, New York).  Infants received a 2 dose priming schedule at 8 and 
16 weeks, followed by a booster at 12 months.  This programme led to a rapid reduction in vaccine-
type and overall IPD across all age groups, both directly and indirectly through a reduction in 
nasopharyngeal carriage of vaccine serotypes[7].  A small and steady increase in IPD due to non-
PCV7 serotypes (serotype replacement) was observed in children and adults after PCV7 introduction 
[8].  
 
In April 2010, this vaccine was replaced by a 13-valent vaccine (PCV13, Prevenar13®, Pfizer), which 
provided additional protection against some of the major replacing serotypes, including 7F and 19A 
[9]. This programme led to further reductions in vaccine-type and overall IPD, and was also 
associated with an increase in replacement disease due to non-PCV13 serotypes [9].  Because of the 
current low rates of PCV13-type IPD, the UK vaccination advisory committee (the Joint Committee 
on Vaccination and Immunisation, JCVI) have recently recommended reducing the number of infant 
priming doses to a single dose at 3 months of age [10]. 
 
During the PCV7 era, 23% of infants with IPD in the first 3 months of life had been born prematurely 
compared to a background rate of 7% [11]. Among 3-59 month-olds, 10% of children with IPD had 
been born prematurely and 15% had an underlying co-morbidity [12].  Premature infants have 
reduced antibody responses to pneumococcal conjugate vaccination compared with those born at 
term [13], and these responses are dependent on the primary vaccination schedule received [14].   
 
The impact of PCV13 on IPD following a reduced 2-dose priming schedule in infants and, especially in 
premature infants is not known.  Using national surveillance data, we aimed to describe the 
epidemiology, clinical characteristics, serotype distribution and outcomes of IPD in infants, and to 
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estimate the relative risk of PCV13-type, non-PCV13 type and overall IPD in premature infants 
compared to term infants during a four-year period after the PCV13 programme was established in 
England. 
 
Methods 
Identification of cases 
Public Health England (PHE) conducts enhanced surveillance for IPD in England.  PHE provides a 
national reference laboratory service for serotyping and characterisation of invasive pneumococcal 
isolates. PHE routinely receives electronic reports of invasive pneumococcal isolates from National 
Health Service (NHS) hospital laboratories across England, and actively requests referral of invasive 
isolates to the reference laboratory if not already done.  For confirmed cases, additional clinical 
details including vaccination history, comorbidities, clinical presentations and outcomes are 
obtained from the child’s general practitioner using standard surveillance questionnaires.  In order 
to accurately assign outcomes of IPD and cause of death in fatal cases, all confirmed cases are cross-
checked with the Personal Demographic Service (https://digital.nhs.uk/Demographics) and 
electronic death registration records provided by the Office for National Statistics 
(www.statistics.gov.uk) to PHE.  
Ethical approval 
PHE has legal permission, provided by Regulation 3 of The Health Service (Control of Patient 
Information) Regulations 2002, to process confidential patient information for national surveillance 
of communicable diseases (http://www.legislation.gov.uk/uksi/2002/1438/regulation/3/made). This 
includes PHE’s responsibility to monitor the safety and effectiveness of vaccines. 
Definitions 
An IPD case was defined as culture of S. pneumoniae from a normally sterile site or detection of 
pneumococcal DNA via PCR in the cerebrospinal (CSF), pleural or joint fluid.  For clinical 
presentations with multiple manifestations, the following hierarchy was applied for analysis: 
meningitis, pneumonia, other sites and bacteraemia.  Meningitis was defined as S. pneumoniae 
isolated from the CSF, or clinical, radiological or laboratory features of meningitis with S. 
pneumoniae isolated from the blood culture.  Pneumonia was defined as S. pneumoniae isolated 
from empyema fluid or the blood with radiological or clinical evidence of pneumonia.  Bacteraemia 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy842/5114360 by St G
eorge's U
niversity of London user on 12 O
ctober 2018
  
was defined as S. pneumoniae cultured from the blood without a distinctive clinical syndrome.  
Multiple samples collected in a 30 day time period from the same individual were regarded as the 
same episode of infection.  In addition to prematurity (birth gestation below 37 weeks), underlying 
conditions associated with IPD were pre-defined as: chronic renal, hepatic, respiratory and cardiac 
disease, diabetes mellitus, CSF leak or cochlear implants, and asplenia or splenic dysfunction [15]. 
PCV13 serotypes include: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.  PCV13 breakthrough 
cases were defined as IPD caused by a PCV13 serotype at least 14 days after receiving a PCV13 dose.  
Data analysis 
All confirmed IPD cases diagnosed in infants (aged <1 year) between 01 January 2013 and 31 
December 2016 were included in the analysis.  Data were analysed using Stata 13 (StataCorp, Texas, 
USA).  Population estimates, including data on premature births, were obtained from the Office of 
National Statistics [16].  In cases where the serotype was not known, it was assumed that they had 
the same PCV13/non-PCV13 serotype distribution as the serotyped cases.  Incidence rate ratios (IRR) 
were calculated with exact 95% confidence intervals (CI) using binomial probabilities. Non-
parametric data are described using medians and interquartile ranges (IQR).  Proportions were 
compared using the Χ2 or Fisher exact test, as appropriate. 
 
Results 
Study Population 
During the four year period, there were 517 cases of IPD in infants, and 291 (56.3%) were male.  The 
overall IPD incidence was 19/100,000 infants.  There was an increase in the incidence of all-serotype 
IPD from 17/100,000 infants in 2013 to 23/100,000 infants in 2016 (IRR 1.35, 95% CI 1.04-1.71, 
p=0.019).  The median age at presentation was 165 days (IQR 63-269), with 49 cases (9.5%) 
occurring in the first 7 days and 158 (30.6%) in the first three months of life.  IPD incidence in infants 
aged <90 days was 16/100,000 live births.  Overall, 99 (19.1%) infants had been born prematurely, 
67 (13.0%) had clinical risk factors (excluding prematurity) for IPD and 148 (28.6%) had been born 
prematurely and/or had risk factors for IPD (Table 1).  
Prematurity 
The overall incidence of IPD was significantly higher in premature infants compared with those born 
at term (49/100,000 vs 17/100,000, incidence rate ratio 2.87; 95% CI, 2.28-3.59, p<0.001) with 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy842/5114360 by St G
eorge's U
niversity of London user on 12 O
ctober 2018
  
infants born at below 28 weeks having the highest incidence (incidence rate 150/100 000, IRR 8.77; 
CI 4.63-15.16, p<0.001 compared with term infants).  In premature infants, a higher proportion of 
cases occurred in the first month (27/97 [27.8%] vs. 38/420 [9.0%]; p<0.001) and particularly in the 
first two days of life (23/97 [23.7%) vs. 18/420 [4.3%]; p<0.001) compared to term infants.   The 
median age (IQR) was 119 (17-234) days for premature infants compared to 177 (74-277) days in 
infants born at term (p<0.001). Premature infants had a higher incidence of both PCV13 and non-
PCV13 IPD compared with term infants (Table 2) and both the absolute incidence and the relative 
risk declined with age (Table 3). 
 
 
 
Clinical Presentation 
Meningitis was the most common clinical presentation (222 cases, 42.6%), followed by septicaemia 
(164 cases, 31.7%), pneumonia (122 cases, 23.6%) and other sites (11 cases, 2.1%), including joint 
(n=10) and soft tissue (n=1) infections.  Meningitis cases were diagnosed from birth and declined 
after 7 months of age; this trend was observed among both PCV13 and non-PCV13 serotypes causing 
meningitis. The majority of meningitis cases occurred in healthy infants born at term (185 cases, 
84.1%).  Of the 418 term infants with IPD, 49 (11.7%) had comorbidities.  Infants with underlying 
conditions were more likely to have bacteraemia or pneumonia while previously healthy infants 
were likely to develop meningitis (p=0.004).   
Serotypes 
Of the 454 IPD cases with serotyped isolates, most were caused by non-PCV13 serotypes (369 cases, 
71.4%) with 85 cases (16.4%) due to PCV13 serotypes.  The most common non-PCV13 serotypes 
causing IPD were serotypes 12F and 8 (43 cases each, 9.5%) and 10A (40 cases, 8.8%) (Figure 1).  Of 
PCV13 serotypes, serotype 3 dominated among premature (13/23, 56.5%) and term (21/62, 33.9%) 
infants, as well as serotypes 19A and 7F in the latter.  
Whilst the total number of IPD cases increased over the study period (from 115 in 2013 to 153 in 
2016), the proportion of PCV13-serotype cases dropped from 31.3% (36 cases) in 2013 to 18.3% in 
2016 (28 cases) (p=0.023).   The serotype distribution varied during the first year of life (Figure 2). 
Overall, 50/143 (35.0%) cases in the first two months of life (pre-vaccination) were due to PCV13 
serotypes compared to 35/311 (11.8%) in older infants (p<0.001).  Non-PCV13 serotypes were 
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responsible for 51/60 (85%) IPD cases in infants with underlying conditions and 318/394 (80.7%) 
cases in healthy children (p=0.42).    
PCV13-type IPD after vaccination 
There were 85 PCV13-serotype cases in our cohort, 24 (28%) in preterm infants and 61 (72%) in term 
infants.  In preterm infants, 15 were too young for vaccination, both infants who were eligible for 
one dose were unvaccinated prior to developing IPD (serotypes 3, 19A); of those who were eligible 
for 2 doses (7 infants), one was unvaccinated (serotype 7F), three had received one dose (all 
serotype 3) and the three appropriately vaccinated infants developed IPD (two serotype 3 and one 
19A).  In term infants, 26 were too young to be vaccinated, 3/12 who were eligible for the first dose 
were unvaccinated prior to developing IPD (serotypes 3, 7F, 19F) and the remaining 9 developed IPD 
due to serotypes 7F (8 cases) and 19A. Of the 23 eligible for 2 doses, 2 were unvaccinated (serotypes 
7F, 19F), 3 had received a single dose only (two serotypes 7F, one serotype 3) and the 18 
appropriately vaccinated infants developed IPD due to serotypes 3 (6), 19A (5), 1 (2) and one case 
each of serotypes 6B, 7F, 18C, 19F and 23F.  Therefore, 6/9 (67%) preterm infants and 8/35 (23%) 
term infants were under-vaccinated prior to developing PCV13-type IPD (P=0.012). 
 Case Fatality Rate (CFR) 
There were 31 deaths (CFR 6.2%; 95% CI, 4.3-8.6%), including 7 in children with comorbidities.  CFR 
in previously healthy infants was 5.3% (24/450 cases) compared to 10.4% in infants with co-
morbidities (7/67 cases; p=0.10).  There were 7 deaths in infants born prematurely (CFR 7.1%) 
compared with 24 (5.7%) in infants born at term (p=0.62).  Twelve infants with bacteraemia died 
(12/164, 7.3%), 8 with meningitis (8/222, 3.6%) and 11 with pneumonia (11/122, 9.0%). Of the 23 
deaths with known serotypes, 5 were associated with PCV13 serotypes (Supplementary Table 1).   
 
Discussion 
Our study focused on infants in their first year of life with IPD in the post-PCV13 era.  We found that 
infants born prematurely continue to have an increased risk of IPD compared with infants born at 
term for both PCV13 and non-PCV13 serotypes, and that this risk was highest in the first month of 
life.  Currently, in infants, most PCV13-type IPD cases occur either before PCV13 vaccination or in 
those partially-immunised.   
 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy842/5114360 by St G
eorge's U
niversity of London user on 12 O
ctober 2018
  
The successes of both the PCV7 and PCV13 programmes in the UK are remarkable [9] with near 
elimination of IPD due to the vaccine serotypes. The few cases of PCV13-type IPD, however, indicate 
that some of these serotypes, especially 3 and 19A, continue to circulate in the community and 
highlight the importance of timely immunisation for infants, including those born prematurely.  
 
IPD in premature infants 
In our cohort, premature infants had a higher risk of both PCV13 and non-PCV13 type IPD compared 
to those born at term; this risk increased with increasing prematurity and decreased with postnatal 
age.  Premature infants are known to have an increased risk of infectious diseases, including vaccine-
preventable infections [17–19].  A study of 6,000 low birth weight and premature infants in the USA 
prior to PCV introduction revealed a 1.6-2.6 fold increase in IPD compared with normal weight, term 
infants [19].  There have been few studies looking at PCV impact in term and premature infants. 
Ruckinger et al compared IPD rates before and after the introduction of PCV7 into the German 
national immunisation schedule.  They included all cases in children up to 15 years of age and, 
although they identified only 22 children born prematurely, they noted a comparable reduction in 
IPD rates in those born at term (15.0 to 8.5/100,000; 43% reduction) and those born prematurely 
(26.1 to 16.7/100,000; 36% reduction) between 2000 and 2007.  The IPD incidence in premature 
infants remained nearly twice as high as children who had been born at term [17].  This increased 
risk of IPD and other vaccine-preventable diseases is likely to be due to a combination of reasons, 
including an immature immune system, reduced transplacental transfer of maternal antibodies, 
delayed immunisation, prolonged hospitalisation and ongoing medical conditions [20–23].  Previous 
studies have shown reduced immunogenicity of pneumococcal conjugate vaccines in infants born 
prematurely, particularly those receiving reduced primary immunisation schedules [14,20].  Our 
findings confirm an ongoing increased risk of vaccine preventable IPD in premature infants in the 
post-PCV13 era. Differences in clinical presentation and serotype distribution may be due to 
premature infants developing early-onset IPD, most likely through vertical transmission, and 
presenting with septicaemia, while term infants are more likely to acquire the infection through 
horizontal transmission, develop IPD at a later age and present with meningitis and other focal 
infections [11]. 
 
PCV13 serotype IPD 
We found a significant proportion of infants who developed PCV13-type IPD were delayed with their 
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pneumococcal vaccinations, emphasising the importance of timely immunisation in this vulnerable 
group [13,14,24].  Of the PCV13 serotypes causing IPD, serotypes 19A and 3 were overrepresented in 
term and preterm infants.  The estimated vaccine effectiveness against these serotypes – even after 
completion of the nationally recommended schedule – is lower compared to the other PCV13 
serotypes [25] and these two serotypes are the most common cause of vaccine failure in UK children 
[26].   
 
In October 2017, the JCVI recommended a reduction in the UK infant PCV13 schedule to a single 
priming dose at 3 months of age [10].  The success of the current vaccination programme means 
that PCV13 disease is at very low levels in the UK and modelling suggests that the 12 month dose is 
the most important for the reduction of carriage and, therefore, maintaining population (herd) 
protection across all age groups.  In a recent clinical trial, although a single PCV13 priming in term 
infants was less immunogenic than two priming doses, antibody concentrations and proportion of 
infants protected after the 12-month booster for the PCV13 serotypes were similar across both 
groups [27]. Therefore, the continuing population protection offered by the 12-month booster 
should limit exposure of PCV13 serotypes during the vulnerable period between the priming and 
booster vaccinations, even with a reduced PCV13 priming schedule. This could potentially save the 
health service around 800,000 vaccine doses annually and reduce the number of injections to only 
two per primary immunisation. 
 
However, given the increased incidence of IPD in premature infants, any reductions in the priming 
schedule will require careful monitoring in this vulnerable group.  In a previous study a two-dose 
infant priming schedule in premature infants resulted in significantly lower geometric mean 
concentrations for 12 of the PCV13 serotypes compared with infants receiving 3 doses and, prior to 
the 12-month booster, very few infants had protective antibody concentrations against more than 
half the PCV13 serotypes [14].  No clinical trial has been undertaken to assess a single priming dose 
in premature infants. 
 
IPD in infants with underlying health problems 
Individuals with specific conditions are known to have a significantly higher risk of IPD compared to 
their healthy peers [28].  We found a similar prevalence of these co-morbidities in our cohort 
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compared with a comparable cohort in the PCV7 period (both 13%) [12].  Other studies have 
reported similar rates of co-morbidities in children with IPD following PCV13 introduction, with a 
higher prevalence of IPD due to non-PCV13 serotypes in those with underlying health conditions 
compared to healthy infants [29].  Unfortunately, we do not have accurate denominator data on at-
risk conditions in infants to calculate relative incidence and compare relative risks of IPD.  
 
Meningitis is the most severe of all IPD presentations, being responsible for 43% of cases in our 
cohort,  and is responsible for significant morbidity and mortality, with high rates of long-term 
neurodevelopmental sequelae among survivors [3].  CFR in our cohort was 6.2% and 4.4% in a 
previous PCV7 cohort; we do not, however, routinely collect data on neurodevelopmental sequelae. 
This is worthy of further study, especially given that most cases are now due to novel, replacing 
serotypes that are not preventable with current pneumococcal conjugate vaccines. 
 
Strengths and limitations 
The strength of this study lies in the established long-term national surveillance for IPD, alongside a 
national reference laboratory to serotype nearly 95% of all invasive pneumococcal isolates across 
England, which also allows us to compare rates over time.  Since 2010, there is a statutory 
requirement for laboratories to report clinically significant infections to PHE; this process is now 
automated through electronic reporting.  One limitation is the limited data collected in the 
surveillance questionnaire which is completed by the patient’s general practitioner rather than 
hospital clinician. Detailed clinical information on presenting symptoms and signs, laboratory 
investigations, treatment and supportive management, sequelae and long-term follow-up are 
lacking.  It is also possible that the prematurity status of some infants may not be readily identified 
in the general practice electronic database; however, identifying any additional IPD cases in infants 
born prematurely would only serve to increase the estimated incidence in this vulnerable group. Our 
rates should, therefore, be considered a minimum estimate.  
 
Conclusions 
The incidence of IPD in infants remains far lower than rates reported prior to PCV7 introduction in 
England, despite a small increase in disease due to non-PCV13 serotypes. The risk of IPD remains 
significantly higher in infants born prematurely compared to infant born at term, for both PCV13 and 
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non-PCV13 serotypes.  The recent recommendation to reduce the UK 2+1 pneumococcal 
immunisation schedule (2 priming doses plus a booster) to a 1+1 schedule (single priming dose plus 
a booster) will need careful monitoring, especially in premature infants, who may be 
disproportionately affected by this change. 
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Notes 
Conflicts of Interest: The Immunisation Department at Public Health England provides vaccine 
manufacturers (including GSK, MSD, and Pfizer) with post-marketing surveillance reports on vaccine 
preventable diseases, including pneumococcal infections, which the companies are required to 
submit to the UK Licensing Authority in compliance with their Risk Management Strategy. A cost 
recovery charge is made for these reports. CLS and NKF as employees of the Respiratory and Vaccine 
Preventable Bacteria Reference Unit have received research funding from Pfizer and 
GlaxoSmithKline but receive no personal remuneration. The PHE Respiratory and Vaccine 
Preventable Bacteria Reference Unit has provided pneumococcal serotyping surveillance reports to 
Affinivax. A cost recovery charge is made for these reports. PTH & SNL perform contract research for 
vaccine manufacturers (including GSK, Pfizer, and Sanofi Pasteur) on behalf of St George’s University 
of London and Public Health England (London, UK), respectively, but receive no personal 
remuneration. All other authors declare no competing interests. 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy842/5114360 by St G
eorge's U
niversity of London user on 12 O
ctober 2018
  
References 
1.  GBD 2015 Mortality and Causes of Death Collaborators H, Naghavi M, Allen C, et al. Global, 
regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 
249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 
2015. Lancet (London, England) 2016; 388:1459–1544.  
2.  Askim Å, Mehl A, Paulsen J, et al. Epidemiology and outcome of sepsis in adult patients with 
Streptococcus pneumoniae infection in a Norwegian county 1993–2011: an observational 
study. BMC Infect. Dis. 2016; 16:223.  
3.  Stockmann C, Ampofo K, Byington CL, et al. Pneumococcal meningitis in children: 
Epidemiology, serotypes, and outcomes from 1997-2010 in Utah. Pediatrics 2013; 132:421–
428.  
4.  Geno KA, Gilbert GL, Song JY, et al. Pneumococcal capsules and their types: Past, present, and 
future. Clin. Microbiol. Rev. 2015; 28:871–899.  
5.  Burton RL, Geno KA, Saad JS, Nahm MH. Pneumococcus with the “6E” cps locus produces 
serotype 6B capsular polysaccharide. J. Clin. Microbiol. 2016; 54:967–971.  
6.  Eletu SD, Sheppard CL, Thomas E, et al. Development of an extended-specificity multiplex 
immunoassay for detection of streptococcus pneumoniae serotype-specific antigen in urine 
by use of human monoclonal antibodies. Clin. Vaccine Immunol. 2017; 24:e00262-17.  
7.  Flasche S, van Hoek AJ, Sheasby E, et al. Effect of pneumococcal conjugate vaccination on 
serotype-specific carriage and invasive disease in England: A cross-sectional study. PLoS Med. 
2011; 8:14.  
8.  Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype 
replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and 
Wales: an observational cohort study. Lancet Infect. Dis. 2011; 11:760–768.  
9.  Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. Effect of the 13-valent 
pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 
years after its introduction : an observational cohort study. Lancet Infect. Dis. 2015; 3099:1–
9.  
10.  JCVI. Joint Committee on Vaccination and Immunisation Meeting minutes. 2017.  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy842/5114360 by St G
eorge's U
niversity of London user on 12 O
ctober 2018
  
11.  Ladhani SN, Andrews NJ, Waight P, Borrow R, Slack MPE, Miller E. Impact of the 7-valent 
pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 
90 days in England and wales. Clin. Infect. Dis. 2013; 56:633–40.  
12.  Ladhani SN, Slack MPE, Andrews NJ, Waight P a, Borrow R, Miller E. Invasive pneumococcal 
disease after routine pneumococcal conjugate vaccination in children, England and Wales. 
Emerg. Infect. Dis. 2013; 19:61–8.  
13.  Martinón-torres F, Czajka H, Wysocki J. 13-Valent pneumococcal conjugate vaccine ( PCV13 ) 
in preterm versus term infants. Pediatrics 2015; 135.  
14.  Kent A, Ladhani SN, Andrews NJ, et al. Schedules for pneumococcal vaccination of preterm 
infants : An RCT. Pediatrics 2016; 138:e20153945.  
15.  Department of Health. Chapter 25: Pneumococcal. In: Immunisation against Infectious 
Diseases (The Green Book). 2010: 295–312.  
16.  Office for National Statistics. Birth Characterisitics. Available at: 
https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirt
hs/datasets/birthcharacteristicsinenglandandwales. Accessed 31 August 2017. 
17.  Rückinger S, van der Linden M, von Kries R. Effect of heptavalent pneumococcal conjugate 
vaccination on invasive pneumococcal disease in preterm born infants. BMC Infect. Dis. 2010; 
10:12.  
18.  Hjuler T, Wohlfahrt J, Simonsen J, et al. Perinatal and crowding-related risk factors for 
invasive pneumococcal disease in infants and young children: a population-based case-
control study. Clin. Infect. Dis. 2007; 44:1051–6.  
19.  Shinefield H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E. Efficacy, immunogenicity and 
safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm 
infants. Pediatr. Infect. Dis. J. 2002; 21:182–6.  
20.  Ruggeberg JU, Collins C, Clarke P, et al. Immunogenicity and induction of immunological 
memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine 
2007; 25:264–71.  
21.  Heath PT, Booy R, McVernon J, et al. Hib vaccination in infants born prematurely. Arch. Dis. 
Child. 2003; 88:206–10.  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy842/5114360 by St G
eorge's U
niversity of London user on 12 O
ctober 2018
  
22.  Lee YC, Kelly DF, Yu L-M, et al. Haemophilus influenzae type b vaccine failure in children is 
associated with inadequate production of high-quality antibody. Clin. Infect. Dis. 2008; 
46:186–92.  
23.  van den Berg JP, Westerbeek E a M, van der Klis FRM, Berbers G a M, van Elburg RM. 
Transplacental transport of IgG antibodies to preterm infants: a review of the literature. Early 
Hum. Dev. 2011; 87:67–72.  
24.  Moss SJ, Fenton AC, Toomey JA, Grainger AJ, Smith J, Gennery AR. Responses to a conjugate 
pneumococcal vaccine in preterm infants immunized at 2, 3, and 4 months of age. Clin. 
Vaccine Immunol. 2010; 17:1810–6.  
25.  Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of 
protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort 
study. Lancet Infect. Dis. 2014; 3099:1–8.  
26.  Oligbu G, Collins S, Andrews N, et al. Characteristics and serotype distribution of childhood 
cases of invasive pneumococcal disease following pneumococcal conjugate vaccination in 
England and Wales, 2006–2014. Clin. Infect. Dis. 2017; 65:1191–1198.  
27.  Goldblatt D, Southern J, Andrews NJ, et al. Pneumococcal conjugate vaccine 13 delivered as 
one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 
+ 1) in UK infants: A multicentre, parallel group randomised controlled trial. Lancet Infect. Dis. 
2017; 18:171–179.  
28.  van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the 
risk of developing invasive pneumococcal disease in England. J. Infect. 2012; 65:17–24.  
29.  Tam P-YI, Madoff LC, Coombes B, Pelton SI. Invasive Pneumococcal Disease After 
Implementation of 13-Valent Conjugate Vaccine. Pediatrics 2014; 134:210–217.  
 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy842/5114360 by St G
eorge's U
niversity of London user on 12 O
ctober 2018
  
Tables 
Table 1: Characteristic of infants with IPD  
 
Term Preterm 
<28 weeks 
gestation 
28-<32 weeks 
gestation 
32-<37 weeks 
gestation 
Number of IPD cases  419 (81) 99 (19) 13 (3) 21 (4) 64 (12) 
Population 2437959 199100 8646 21121 169333 
Incidence (per 100 
000) 
17 49a 15 a 99 a 38 a 
Age at IPD 
<7 days 25 (6) 24 (24) 5 (38) 9 (43) 10 (16) 
7-89 days 94 (22) 15 (15) 1 (7) 4 (19) 9 (14) 
≥90 days 299 (72) 60 (60) 7 (54) 8 (38) 45 (70) 
Risk factors 
Any 49 (12) 18 (18) 3 (23) 5 (24) 10 (16) 
Chronic heart disease 23 (5) 5 (5) 0 (0) 1 (5) 4 (6) 
Chronic respiratory 
condition 
10 (2) 6 (6) 1 (7) 4 (2) 1 (1) 
Asplenia or dysfunction 5 (1) 3 (3) 0 (0) 0 (0) 3 (5) 
Cochlear implant 2 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
CSF leak 3 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
Chronic liver disease  2 (<1) 1 (1) 0 (0) 0 (0) 1 (1) 
Chronic renal disease 2 (<1) 1 (1) 1 (7) 0 (0) 0 (0) 
Immunosuppression 1 (<1) 2 (2) 1 (7) 0 (0) 1 (1) 
Diabetes 1 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
Presentation 
Bacteraemia 119 (28) 46 (46) 7 (54) 12 (57) 26 (41) 
Meningitis 196 (47) 24 (24) 0 (0) 6 (29) 18 (28) 
Pneumonia 93 (22) 29 (29) 6 (46) 3 (14) 20 (31) 
Other 11 (3) 0 (0) 0 (0) 0 (0) 0 (0) 
Serotype group 
PCV13 61 (15) 24 (24) 4 (31) 9 (43) 11 (17) 
Non-PCV13 302 (72) 68 (69) 9 (69) 10 (48) 48 (75) 
Not serotyped 56 (13) 7 (7) 0 (0) 2 (10) 5 (8) 
Died 24 (6) 7 (7) 0 (0) 3 (14) 4 (6) 
Cases (%).  a Statistically significant difference compared to term infants (p-value<0.05).  
One premature infant had unknown gestation. 
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Table 2: Incidence rates and ratios for preterm infants 
 Incidence rate 
(premature) 
Incidence rate 
(term) 
IRR (95% CI) p-value 
All serotypes 
<28 weeks 150/100 000 
17/100 000 
8.77 (4.63-15.16) <0.001 
28-32 weeks 99/100 000 5.80 (3.55-8.98) <0.001 
32-37 weeks 38/100 000 2.20 (1.67-2.87) <0.001 
All <37 49/100 000 2.87 (2.28-3.59) <0.001 
PCV13 serotypes only 
<28 weeks 46/100 000 
3/100 000 
16.11 (4.3-43.1) <0.001 
28-32 weeks 47/100 000 16.5 (7.6-32.2) <0.001 
32-37 weeks 7/100 000 2.5 (1.2-4.6) 0.009 
All <37 13/100 000 4.5 (2.8-7.2) <0.001 
Non-PCV13 serotypes only 
<28 weeks 104/100 000 
14/100 000 
7.3 (3.3-14.0) <0.001 
28-32 weeks 52/100 000 3.6 (1.8-6.6) <0.001 
32-37 weeks 31/100 000 2.1 (1.6-2.9) <0.001 
All <37 36/100 000 2.5 (1.9-3.3) <0.001 
IRR: Incidence rate ratio, CI: confidence interval 
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Table 3: Incidence rates and ratios for age of IPD in preterm and term infants 
 Incidence rate 
(premature) 
Incidence rate 
(term) 
IRR (95% CI) p-value 
All serotypes 
<1 month 162/100 000 19/100 000 8.70 (5.1-14.6) <0.001 
<3 months 80/100 000 19/100 000 3.95 (2.68-5.71) <0.001 
3-11 months 30/100 000 12/100 000 2.47 (1.84-3.27) <0.001 
PCV13 serotypes only 
<1 month 66/100 000 8/100 000 8.41 (3.53-19.30) <0.001 
<3 months 30/100 000 7/100 000 4.59 (2.35-8.50) <0.001 
3-11 months 5/100 000 1/100 000 4.08 (1.78-8.58) <0.001 
Non-PCV13 serotypes only 
<1 month 96/100 000 11/100 000 8.91 (4.37-17.8) <0.001 
<3 months 48/100 000 13/100 000 3.63 (2.20-5.78) <0.001 
3-11 months 25/100 000 11/100 000 2.29 (1.66-3.11) <0.001 
IRR: Incidence rate ratio, CI: confidence interval 
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Figures 
Figure 1: IPD serotypes.   
Legend: 6C included as a PCV13 related serotype.   
 
Figure 2: PCV7, PCV13 and non-PCV7/13 serotypes over the first year of life 
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Figure 1 
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Figure 2 
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